Zheng, Z., Zhu, H., Fang, L. (2025). Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis. PLoS ONE. https://doi.org/10.1371/journal.pone.0320189